Implication of foam sclerosant inactivation by human whole blood in a laboratory setting

Phlebology
Emma B DabbsMark S Whiteley

Abstract

Background During sclerotherapy, it has been recommended to confirm intravenous placement of the needle by aspirating blood into the sclerosant syringe. This may inactivate some, or all of the sclerosant. Aims To quantify the volume of human blood needed to completely inactivate 1 ml of sodium tetradecyl sulphate, and comparing fresh blood and blood that has been stored in an ethylenediaminetetraacetic acid tube. Methods A series of manual titrations were carried out following a procedure developed at STD Pharmaceutical Products Ltd (Hereford, UK) and listed in the British Pharmacopeia. Three percent of sodium tetradecyl sulphate stock solutions were made with increasing volumes of blood and titrated against benzethonium chloride to determine the active concentration (% w/v) of sodium tetradecyl sulphate remaining in the solution. Results A calculated approximation showed 0.3 ml of blood is required to fully inactivate 1 ml of 3% sodium tetradecyl sulphate when made into a foam. A comparison was made between the use of fresh blood and blood stored in ethylenediaminetetraacetic acid tubes. Blood stored in ethylenediaminetetraacetic acid tubes showed more inactivation of sodium tetradecyl sulphate, but this was not significant at...Continue Reading

References

Oct 28, 2006·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·K A MyersJ Kirwan
Oct 9, 2007·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·K ParsiJ E Joseph
Apr 9, 2008·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·K ParsiJ E Joseph
Jul 22, 2008·Journal of Vascular Surgery·Rodrigo Gonzalez-ZehSergio Barahona
May 16, 2009·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·K ParsiJ E Joseph
May 1, 1946·Proceedings of the Society for Experimental Biology and Medicine·L REINER
Jan 26, 2011·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·M R Watkins
Apr 6, 2013·Phlebology·E RabeUNKNOWN Guideline Group
May 16, 2014·Phlebology·Kurosh Parsi
Feb 18, 2015·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·D E ConnorK Parsi
Jan 23, 2016·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·M S WhiteleyJ M Li
Mar 20, 2016·Journal of Vascular Surgery. Venous and Lymphatic Disorders·Salil B PatelMark S Whiteley
Apr 14, 2016·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·O Cooley-AndradeK Parsi

❮ Previous
Next ❯

Citations

Mar 13, 2021·Cardiovascular and Interventional Radiology·Charlotte L OliverRichard J Oliver
May 28, 2021·Phlebology·Joseph GracéKurosh Parsi

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Software Mentioned

Excel

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

© 2022 Meta ULC. All rights reserved